The DOI matches its Crossref record.
Sarcoplasmic MxA expression: A valuable marker of dermatomyositis
Abstract
OBJECTIVE: To evaluate the diagnostic value of myxovirus resistance A (MxA) expression in the cytoplasm of myofibers in the diagnosis of dermatomyositis (DM). METHODS: We assessed the sensitivity and specificity of the sarcoplasmic expression of MxA in muscles with DM by immunohistochemistry in consecutive cases of DM (n = 34) and other idiopathic inflammatory myopathies (n = 120: 8 with polymyositis, 16 with anti-tRNA-synthetase antibody-associated myositis, 46 with immune-mediated necrotizing myopathy, and 50 with inclusion body myositis) and compared them with conventional pathologic hallmarks of DM, including perifascicular atrophy (PFA) and membrane attack complex (MAC) deposition on endomysial capillaries. RESULTS: The sensitivity and specificity of sarcoplasmic MxA expression were 71% and 98%, respectively. While the specificity was almost comparable to that of PFA and capillary MAC deposition, the sensitivity was higher, with PFA showing 47% sensitivity and 98% specificity and capillary MAC deposition showing 35% sensitivity and 93% specificity. Of note, in patients with DM with typical skin rash but no PFA, 44% of the samples showed sarcoplasmic MxA expression, which was higher than the 17% sensitivity of capillary MAC deposition in the population. CONCLUSIONS: Sarcoplasmic MxA expression detected by immunohistochemistry is a more sensitive marker of DM than the conventional hallmarks, indicating its practical utility in the diagnosis of DM. It may well be included in the routine immunohistochemistry panel for myositis. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that immunohistochemistry-detected sarcoplasmic MxA expression accurately identifies patients with dermatomyositis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Classification and management of adult inflammatory myopathies
Selva-O'Callaghan, A., Pinal-Fernandez, I., Trallero-Araguás, E., Milisenda, J. C., Grau-Junyent, J. M., & Mammen, A. L. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30254-0 · Cited by 430
Current Classification and Management of Inflammatory Myopathies
Schmidt, J. (2018) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-180308 · Cited by 324
Kamiya, M., Kimura, N., Umezawa, N., Hasegawa, H., & Yasuda, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1191815 · Cited by 21
Metadata
- Authors
- Uruha, A., Nishikawa, A., Tsuburaya, R. S., Hamanaka, K., Kuwana, M., Watanabe, Y., Suzuki, S., Suzuki, N., & Nishino, I.
- Venue
- Neurology
- Published
- 2017-01-31
- Volume
- 88
- Issue
- 5
- Pages
- 493-500
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2564946112
- Cited by
- 164
- References
- 0
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sarcoplasmic MxA expression: A valuable marker of dermatomyositis. https://app.cochat.ai/papers/10.1212/wnl.0000000000003568
- The paper
- Uruha, A., Nishikawa, A., Tsuburaya, R. S., Hamanaka, K., Kuwana, M., Watanabe, Y., Suzuki, S., Suzuki, N., & Nishino, I. (2017). Sarcoplasmic MxA expression: A valuable marker of dermatomyositis. Neurology. https://doi.org/10.1212/wnl.0000000000003568
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.